Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary.

摘要: Summary. Background: Light transmittance aggregometry (LTA) is considered to be the ‘gold standard’ of platelet function testing. As LTA has been poorly standardized, we analyzed results in healthy subjects and patients with antiplatelet therapy using different concentrations agonists performing tests non-adjusted count-adjusted platelet-rich plasma (PRP). Methods: LTA was performed 20 treated aspirin (n = 30) or clopidogrel monotherapy, as well on combination (n = 20), arachidonic acid (ARA 0.25 0.5 mg mL−1) adenosine diphosphate (ADP 2 5 μm) count (250 nL−1 ± 10%)-adjusted PRP. Results: The overall aggregation response decreased after adjusting PRP for compared measurements unadjusted The variability high adjusted subgroup subjects, ranging from 9.2–95.3% (5th–95th percentile) relative 77.6–95.5% when determining maximum ARA 0.5 mg mL−1. Late ADP 2 μm ranges 3.8–89.9% 42.9–92.5% Maximum 0.5 mg mL−1 differentiates between aspirin-treated controls well, whereas late offers best discrimination clopidogrel-treated controls. Conclusion: Adjustment does not provide any advantage therefore time-consuming process adjustment necessary.